This inventor holds 2 USPTO granted patents and 4 published patent applications and 2 EPO patents. Top assignee: Novo Nordisk A/s. Active years: 2019-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2020
Title: Holger Martin Strauss: Innovator in Diabetes Treatment
Introduction
Holger Martin Strauss is a notable inventor based in Frederiksberg, Denmark. He has made significant contributions to the field of pharmaceutical compositions, particularly in the treatment of diabetes. With a total of 2 patents, Strauss has focused on developing innovative solutions to improve the lives of individuals with diabetes.
Latest Patents
His latest patents revolve around insulin-containing pharmaceutical compositions. These inventions are specifically designed for the treatment of medical conditions related to diabetes. The compositions comprise a long-acting acylated derivative of a human insulin analogue, which is intended for basal insulin administration therapy. This advancement represents a crucial step in enhancing the effectiveness of diabetes management.
Career Highlights
Holger Martin Strauss is currently associated with Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care. His work at Novo Nordisk has allowed him to contribute to groundbreaking research and development in the field of diabetes treatment. His expertise and innovative mindset have positioned him as a key player in the pharmaceutical industry.
Collaborations
Throughout his career, Strauss has collaborated with talented professionals, including Mathias Norrman and Susanne Hostrup. These collaborations have fostered a dynamic environment for innovation and have led to the successful development of new pharmaceutical solutions.
Conclusion
Holger Martin Strauss is a distinguished inventor whose work in diabetes treatment has made a significant impact on the pharmaceutical industry. His innovative patents and contributions to Novo Nordisk A/S highlight his commitment to improving healthcare for individuals with diabetes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
